Table 2.

Multivariate analysis of risk factors for development of peripheral neuropathy

Variable	Unadjusted Analysis	P-Value	Adjusted Analysis	P-Value
Age (ref < 40)	1.78 (1.35 to 2.35)	<0.0001	1.65 (1.24 to 2.19)	0.0006
Female Sex	1.27 (0.96 to 1.67)	0.10	1.23 (0.92 to 1.65)	0.16
Baseline CD4 Count cells/UL (Ref < 50)		0.48		0.44
50–100	1.24 (0.85 to 1.82)		1.22 (0.82 to 1.81)
100–150	1.23 (0.86 to 1.74)		1.27 (0.88 to 1.82)
150–200	0.93 (0.63 to 1.39)		1.02 (0.68 to 1.54)
>200	1.22 (0.83 to 1.80)		1.38 (0.92 to 2.07)
Dose (ref = 30mg)	2.03 (1.58 to 2.61)	<0.0001	2.10 (1.61 to 2.74)	<0.0001
Past TB	0.88 (0.65 to 1.18)	0.39	0.91 (0.67 to 1.25)	0.57
Current TB Treatment	1.12 (0.86 to 1.47)	0.39	1.41 (1.06 to 1.87)	0.02
Diabetes	1.86 (0.46 to 7.47)	0.38	1.24 (0.88 to 1.82)	0.77
Weight	1.02 (1.01 to 1.03)	0.003	1.0 (0.99 to 1.02)	0.30
Viral Load copies/ml (n=330)	1.14 (0.95 to 1.38)	0.15	1.11 (0.91 to 1.34)	0.32